Date | Open(₹) | High(₹) | Low(₹) | Close(₹) | No. Of Trades(₹) | Total Turnover(₹) | Deliverable Quantity(₹) |
|---|---|---|---|---|---|---|---|
22-Apr-2026 | 400.9 | 413.8 | 396.5 | 408.35 | 16,615 | 15,83,12,687.45 | 1,61,960 |
23-Apr-2026 | 407.9 | 436.4 | 405.05 | 427.6 | 43,121 | 59,98,89,337.3 | 6,71,553 |
24-Apr-2026 | 434.85 | 435.35 | 412 | 413.9 | 18,072 | 17,69,89,588.45 | 1,84,021 |
27-Apr-2026 | 408.6 | 429 | 407 | 415.2 | 18,299 | 16,12,80,936.35 | 1,75,366 |
28-Apr-2026 | 415.15 | 418.5 | 405.1 | 407.8 | 12,118 | 11,50,00,997.8 | 1,32,627 |
29-Apr-2026 | 409 | 413.15 | 400.6 | 404.05 | 11,295 | 8,57,88,657.45 | 87,572 |
30-Apr-2026 | 404.05 | 414.95 | 400.9 | 406.65 | 14,483 | 13,77,13,838.4 | 1,32,658 |
04-May-2026 | 410.65 | 425.95 | 409 | 418.7 | 19,925 | 17,64,72,750.3 | 1,80,682 |
05-May-2026 | 415.85 | 436.35 | 408.05 | 424.4 | 24,562 | 41,98,50,574.6 | 5,41,733 |
06-May-2026 | 424.4 | 448.9 | 424.35 | 441.9 | 36,247 | 44,59,29,240.05 | 4,56,815 |
07-May-2026 | 443.8 | 451 | 437 | 441.7 | 17,168 | 18,29,19,143.75 | 1,87,577 |
08-May-2026 | 438 | 447.7 | 432.05 | 437 | 23,236 | 30,49,41,732.5 | 3,45,489 |
11-May-2026 | 434.25 | 478 | 426.15 | 456.15 | 47,220 | 82,23,60,964.5 | 6,37,716 |
12-May-2026 | 459.55 | 459.55 | 433.7 | 438.65 | 18,883 | 18,80,44,944.3 | 1,94,723 |
13-May-2026 | 439 | 452.5 | 435.05 | 438.85 | 21,927 | 22,42,11,853.3 | 2,17,950 |
14-May-2026 | 438.35 | 453.8 | 432.5 | 450.5 | 16,328 | 20,97,17,285.1 | 1,98,860 |
15-May-2026 | 452.3 | 491.95 | 450 | 478.4 | 64,323 | 1,16,77,80,672.75 | 9,27,776 |
18-May-2026 | 479 | 493.2 | 473.05 | 476.2 | 34,135 | 48,32,17,200.4 | 4,25,592 |
19-May-2026 | 476.95 | 490.75 | 464.15 | 472.45 | 26,165 | 26,35,07,912.25 | 1,69,934 |
20-May-2026 | 471.15 | 483.8 | 466.85 | 476.3 | 19,749 | 18,14,25,252.85 | 1,79,409 |
21-May-2026 | 479.9 | 486.85 | 468.05 | 474.65 | 18,008 | 30,32,09,196.4 | 3,14,291 |
It targets to initiate first-in-human clinical trials in patients with Essential Thrombocythemia and Polycythemia Vera.
Here are some of the stocks that may see significant price movement today: Larsen & Toubro, Lodha Developers, Shilpa Medicare, etc.
USFDA conducted the Good Manufacturing Practices (GMP) inspection from October 24 to October 30 in 2024.
The certification came after a successful inspection by the Finnish Medicines Agency on behalf of EMA from March 10 to March 14, 2025
The partnership will work on a new biological entity (NBE) in the immuno-oncology field to better treat cancer.
Here are some of the stocks that may see significant price movement today: Aditya Birla Real Estate, Shilpa Medicare, Swiggy, etc.
No regulatory issues were raised by the USFDA at Unit-2 during the inspection, the company said in a regulatory filing.
Shilpa Medicare said it has completed Phase 3 trials for SMLNUD07 – Nor Ursodeoxycholic Acid (Nor UDCA) tablets in 165 NAFLD patients in India.
The certification followed a successful inspection by the European Medicines Agency, Austria, held from September 24 to September 26 at the Nacharam, Hyderabad facility.
This FDA approval is a milestone in cancer therapy as it presents a more convenient and precise alternative to the traditional tablet forms.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
